Immix Biopharma Announces 89% Success Rate for NXC-201 in AL Amyloidosis Trial
Immix Biopharma reported a 89% complete response rate across late-stage AL Amyloidosis patients. This strong interim data strengthens the company's claim of developing a potential best-in-class therapy.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed